Literature DB >> 31758262

Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases.

Xiang-Gui Yuan1, Yu-Rong Huang1, Teng Yu1, Yang Xu1, Yun Liang1, Xiao-Hong Zhang1, Chong-Ran Sun2, Xiao-Ying Zhao3.   

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin's lymphoma and a limited number of cases have been reported from China. This study aimed to investigate the clinicopathological features of newly diagnosed PCNSLs from a single center in eastern China and to identify the potential prognostic factors for overall survival (OS) and progression-free survival (PFS). All consecutive patients with histopathologically diagnosed PCNSLs at our center between January 2003 and October 2017 were recruited. Demographic and clinicopathological data were collected and reviewed retrospectively. The potential risk factors for OS and PFS were identified using the log-rank test and Cox regression analysis. A total of 167 immunocompetent cases were enrolled. The median age was 58 years (range 17-96 years), and the male:female ratio was 3:2. Headache (n = 65; 39%) and cerebral hemisphere (n = 96; 57%) were the most common presenting complaint and location, respectively. Out of 167 cases, 150 cases were diffuse large B cell lymphomas. With a median follow-up of 25 months (range 1-152 ), the median OS and PFS were 37 months (95% CI, 25-49) and 17 months (95% CI, 13-20), respectively. Residual tumor after operation, chemotherapy without HD-MTX and palliative treatment was revealed as independent prognostic markers. Moreover, ECOG > 3, multifocal lesions, and palliative treatment were revealed as unfavorable independent prognostic markers for PFS. In conclusion, Chinese patients with PCNSL have distinct characteristics. Further studies are warranted to confirm the prognostic value of these factors and to optimize treatments for these patients.

Entities:  

Keywords:  Chinese; Extranodal non-Hodgkin’s lymphoma; Multifocal lesions; Primary central nervous system lymphoma; Prognostic factors; Surgery resection

Mesh:

Year:  2019        PMID: 31758262     DOI: 10.1007/s00277-019-03821-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

1.  Tirabrutinib maintenance therapy for a patient with high-dose methotrexate-ineligible primary central nervous system lymphoma.

Authors:  Tadashi Okamura; Hiroki Hosoi; Takeshi Matsufusa; Yuina Akagi; Ryuta Iwamoto; Hideki Kosako; Shogo Murata; Toshiki Mushino; Shin-Ichi Murata; Takashi Sonoki
Journal:  Ann Hematol       Date:  2022-01-27       Impact factor: 3.673

2.  Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).

Authors:  Yanxia Liu; Qingmin Yao; Feng Zhang
Journal:  Int J Oncol       Date:  2021-02-01       Impact factor: 5.650

3.  Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India.

Authors:  Bishan Dass Radotra; Mayur Parkhi; Debajyoti Chatterjee; Budhi Singh Yadav; Nagarjun Rao Ballari; Gaurav Prakash; Sunil Kumar Gupta
Journal:  Surg Neurol Int       Date:  2020-12-11

4.  Optical Coherence Tomography Benefits the Diagnosis and Follow-Up of Primary Central Nervous System Lymphoma with Intraocular Involvement.

Authors:  Xianjin Zhou; Sha Tian; Xian Zhou; Huimin Shi; Yi Li; Jianjiang Xiao; Kun Chen; Bobin Chen; Gezhi Xu; Qingping Wang
Journal:  Cancer Manag Res       Date:  2022-03-05       Impact factor: 3.989

5.  Clinical Impact of the Histopathological Index and Neuroimaging Features Status in Primary Central Nervous System Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Analysis of 51 Cases.

Authors:  Zhou Qi; Lei Duan; Guoqiang Yuan; Jianli Liu; Jian Li; Guoqiang Li; Yue Yu; Yanlong Xu; Shangxian Ma; Yawen Pan; Yinian Zhang
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

Review 6.  Role of Positron Emission Tomography in Primary Central Nervous System Lymphoma.

Authors:  Laura Rozenblum; Caroline Houillier; Carole Soussain; Marc Bertaux; Sylvain Choquet; Damien Galanaud; Khê Hoang-Xuan; Aurélie Kas
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

Review 7.  Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.

Authors:  Tong Chen; Yuanbo Liu; Yang Wang; Qing Chang; Jinsong Wu; Zhiliang Wang; Daoying Geng; Jin-Tai Yu; Yuan Li; Xiao-Qiu Li; Hong Chen; Dongxiao Zhuang; Jianyong Li; Bin Wang; Tao Jiang; Lanting Lyu; Yuqin Song; Xiaoguang Qiu; Wenbin Li; Song Lin; Xinghu Zhang; Dehong Lu; Junqiang Lei; Yaolong Chen; Ying Mao
Journal:  J Hematol Oncol       Date:  2022-09-29       Impact factor: 23.168

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.